AOC3 and macular retinal edema: SZV 1287 was patented in 2010 together with other AOC3 inhibitors for the prevention and treatment of diseases related to acute or chronic inflammation, carbohydrate metabolism including diabetes-associated complications (retinopathy and macular edema), adipocyte or vascular endothelial and smooth muscle functions, as well as neurodegeneration [9].